Chemical Senescence Induction in Neurons for Disease Modeling
Solution Overview
Problem
Current methods for modeling neurodegenerative diseases using human pluripotent stem cells face challenges in replicating age-related phenotypes, as the iPSC reprogramming process resets cell age and introduces genetic modifications, making it difficult to systematically and reproducibly induce 'aging' in neurons for disease modeling and drug discovery.
Innovation Solution
A method involving a cocktail of chemical agents, including inhibitors of DNA glycosylase 1, autophagy, and HIV protease, such as SBI-0206965, Lopinavir, and O151, is used to induce cellular senescence in human neurons in vitro, generating chemically induced senescent (CIS) neurons that express senescence-associated biomarkers and exhibit age-related morphological features without genetic modification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If iPSC reprogramming is used to model neurodegenerative diseases, then human genetic background can be captured, but cell age is reset and genetic modifications are introduced, making it difficult to replicate age-related phenotypes
Solution Approach 1:
The patent applies preliminary action by inducing cellular senescence in hPSC-derived neurons before disease phenotype assessment. The chemical cocktail (including DNA glycosylase inhibitor OGG1, autophagy inhibitor chloroquine, and proteasome inhibitor MG132) is administered to pre-age the cells, ensuring they exhibit age-related phenotypes prior to disease modeling experiments
Solution Approach 2:
The patent changes the physiological parameter of cell age by treating hPSC-derived neurons with a chemical cocktail that induces senescence. This transforms young, immortalized cells into aged-like cells with altered epigenetic marks, mitochondrial function, and protein homeostasis, thereby recovering age-related phenotypes without genetic modification
2Reliability
If progerin expression is introduced to induce aging in hPSC-derived neurons, then age-related phenotypes are triggered, but genetic background is altered and phenotype deciphering becomes difficult
Solution Approach 1:
The patent substitutes genetic manipulation (mechanical system of DNA transfection/CRISPR) with chemical treatment. Instead of introducing progerin gene expression through viral vectors or CRISPR, the patent uses a chemical cocktail containing OGG1 inhibitor, chloroquine, and MG132 to induce senescence, thereby avoiding genetic background alteration while achieving age-related phenotype induction
Solution Approach 2:
The patent introduces chemical agents as intermediaries to induce cellular aging. The cocktail of small molecules (OGG1 inhibitor, autophagy inhibitor, proteasome inhibitor) acts as mediators that trigger senescence pathways without directly modifying the genome, thus simplifying the model system while maintaining phenotype induction capability
3Ease of manufacture
If direct reprogramming of somatic cells to neurons is used, then small scale efforts are feasible, but large scale production is not feasible and neuron types are limited
Solution Approach 1:
The patent segments the aging process from the differentiation process. First, hPSCs are differentiated into desired neuron types using established protocols (enabling scalable production), then the resulting neurons are treated with the chemical senescence cocktail (enabling age induction). This separation allows independent optimization of both differentiation efficiency and aging induction, solving the scalability limitation of direct reprogramming
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the reliable and reproducible induction of senescence in neurons, enabling effective modeling of neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's, facilitating drug discovery by mimicking age-related phenotypes and accelerating disease phenotype manifestation in stem cell-derived neurons.
Implementation Method 1
contacting human neurons in vitro to a culture medium comprising one or more agents selected from an inhibitor of DNA glycosylase 1
Implementation Method 2
contacting human neurons in vitro to a culture medium comprising one or more agents selected from an inhibitor of DNA glycosylase 1, an autophagy inhibitor
Implementation Method 3
contacting human neurons in vitro to a culture medium comprising one or more agents selected from an inhibitor of DNA glycosylase 1, an autophagy inhibitor, and an HIV protease inhibitor
Implementation Method 4
The CIS neurons can express senescence-associated biomarkers including β-galactosidase and exhibit decreased expression of one or more of H3k9Me3, Lap2β, and HP1γ relative to control neurons
Data Source
AI summary
Provided herein are methods and compositions for inducing chemical senescence in neurons and methods of using chemically induced senescent neurons for modeling neurodegenerative disease and drug discovery. The methods include contacting human neurons with a culture medium comprising an inhibitor of DNA glycosylase 1, an autophagy inhibitor, and an HIV protease inhibitor to obtain an in vitro population of senescent neurons within about 4 days. When the neurons are obtained from a patient having a neurodegenerative disease, chemically induced senescent neurons obtained by these methods recapitulate cellular and subcellular phenotypes observed in individuals with the neurodegenerative disease.



